This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
by Zacks Equity Research
TMO's growth via acquisitions and product launches is strong, but macro pressures and FX headwinds cloud the outlook.
Invest in 4 Winning Stocks With Proven Relative Price Power
by Nilanjan Choudhury
DELL, JBL, PAHC, and HBM are showing strong relative price strength and upward earnings estimates amid a rising market.
Paysafe and Champion Homes have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
PSFE earns Bull of the Day with deep value and rising earnings, while SKY's short surge and weak outlook land it as Bear of the Day.
Phibro (PAHC) Soars 6.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Phibro (PAHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Best Growth Stocks to Buy for July 8th
by Zacks Equity Research
STRT, PAHC and AFYA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 8, 2025.
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It?
by Zacks Equity Research
DGX stock surges 27.3% in a year, fueled by Advanced Diagnostics, key acquisitions and expanding health plan ties.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IART Stock May Rise on First Enrollment in AERA Pediatric Registry
by Zacks Equity Research
Integra enrolls first pediatric patient in AERA registry to evaluate real-world use of its ETBD system and expand ENT market presence.
Teleflex Acquires BIOTRONIK's Vascular Intervention Business, Stock Up
by Zacks Equity Research
TFX gains 2.9% after acquiring BIOTRONIK's vascular unit, boosting its cath lab presence and innovation pipeline.
Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion
by Zacks Equity Research
ABT stock surges 21.7% year to date on CGM sales growth and robust diagnostics demand, even as FX and macro risks weigh on forecasts.
Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Phibro (PAHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now?
by Zacks Equity Research
DGX rides on double-digit diagnostics growth and a wave of strategic acquisitions despite rising debt and policy headwinds.
Boston Scientific Climbs 40.5% in a Year: What's Driving the Stock?
by Zacks Equity Research
BSX rallies 40.5% in a year, fueled by WATCHMAN growth, MedSurg gains, acquisitions and global expansion efforts.
Phibro Animal Health Stock Up 52.8% in a Year: What's Driving the Rise?
by Zacks Equity Research
PAHC stock is under investors' radar due to its booming animal health sales, new product lines and rising vaccine demand.
PAHC vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
PAHC vs. BSX: Which Stock Is the Better Value Option?
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BRKR Stock Gains Following the Multi-System Advanced Packaging Order
by Zacks Equity Research
Bruker ships and installs its 15th InSight WLI system as part of a 27-optical metrology unit order tied to AI chip packaging demand.
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock
by Zacks Equity Research
TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.
Illumina Stock May Benefit From New Agreement to Acquire SomaLogic
by Zacks Equity Research
ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.
Best Growth Stocks to Buy for June 25th
by Zacks Equity Research
OPRX, GLDD and PAHC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 25, 2025
Should You Continue to Retain Abbott Stock in Your Portfolio Now?
by Zacks Equity Research
ABT rides on strong global demand in diagnostics and diabetes care, but macro headwinds may test its momentum ahead.
Is Phibro (PAHC) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.
Why Is Medtronic (MDT) Up 6% Since Last Earnings Report?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
by Zacks Equity Research
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
Reasons to Add PAHC Stock to Your Portfolio Right Now
by Zacks Equity Research
Phibro's strong Animal Health momentum and global expansion bode well for investors.